Počet záznamů: 1  

Molecular targets on mast cells and basophils for novel therapies

  1. 1.
    SYSNO ASEP0435403
    Druh ASEPJ - Článek v odborném periodiku
    Zařazení RIVJ - Článek v odborném periodiku
    Poddruh JČlánek ve WOS
    NázevMolecular targets on mast cells and basophils for novel therapies
    Tvůrce(i) Harvima, I.T. (FI)
    Levi-Schaffer, F. (IL)
    Dráber, Petr (UMG-J) RID
    Friedman, S. (IL)
    Polakovičová, Iva (UMG-J)
    Gibbs, B.F. (GB)
    Blank, U. (FR)
    Nilsson, G. (SE)
    Maurer, M. (DE)
    Zdroj.dok.Journal of Allergy and Clinical Immunology. - : Elsevier - ISSN 0091-6749
    Roč. 134, č. 3 (2014), s. 530-544
    Poč.str.15 s.
    Jazyk dok.eng - angličtina
    Země vyd.US - Spojené státy americké
    Klíč. slovacell activation ; mast cells and basophils ; treatment of allergic diseases
    Vědní obor RIVEB - Genetika a molekulární biologie
    CEPLD12073 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy
    GBP302/12/G101 GA ČR - Grantová agentura ČR
    GA14-09807S GA ČR - Grantová agentura ČR
    GA14-00703S GA ČR - Grantová agentura ČR
    Institucionální podporaUMG-J - RVO:68378050
    UT WOS000341372400004
    DOI10.1016/j.jaci.2014.03.007
    AnotaceMast cells and basophils (MCs/Bs) play a crucial role in type I allergy, as well as in innate and adaptive immune responses. These cells mediate their actions through soluble mediators, some of which are targeted therapeutically by, for example, H1- and H2-antihistamines or cysteinyl leukotriene receptor antagonists. Recently, considerable progress has been made in developing new drugs that target additional MC/B mediators or receptors, such as serine proteinases, histamine 4-receptor, 5-lipoxygenase-activating protein, 15-lipoxygenase-1, prostaglandin D-2, and proinflammatory cytokines. Mediator production can be abrogated by the use of inhibitors directed against key intracellular enzymes, some of which have been used in clinical trials (eg, inhibitors of spleen tyrosine kinase, phosphatidylinositol 3-kinase, Bruton tyrosine kinase, and the protein tyrosine kinase KIT). Reduced MC/B function can also be achieved by enhancing Src homology 2 domain-containing inositol 5' phosphatase 1 activity or by blocking sphingosine-1-phosphate. Therapeutic interventions in mast cell-associated diseases potentially include drugs that either block ion channels and adhesion molecules or antagonize antiapoptotic effects on B-cell lymphoma 2 family members. MCs/Bs express high-affinity IgE receptors, and blocking their interactions with IgE has been a prime goal in antiallergic therapy. Surface-activating receptors, such as CD48 and thymic stromal lymphopoietin receptors, as well as inhibitory receptors, such as CD300a, Fc gamma RIIb, and endocannabinoid receptors, hold promising therapeutic possibilities based on preclinical studies. The inhibition of activating receptors might help prevent allergic reactions from developing, although most of the candidate drugs are not sufficiently cell specific. In this review recent advances in the development of novel therapeutics toward different molecules of MCs/Bs are presented.
    PracovištěÚstav molekulární genetiky
    KontaktNikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217
    Rok sběru2015
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.